News about Clinical Trials

Arletta Pharma Reports Positive Phase II Results for Lybrido in Female Sexual Arousal Disorder

Study shows significant improvement in physiological arousal markers, supporting further development of testosterone-sildenafil combination therapy for FSIAD.

Clinical Trials | 30/03/2026 | By News Bureau

Bristol Myers Squibb Reports Positive Phase 3 SCOUT-HCM Trial Results

Bristol Myers Squibb reports positive Phase 3 SCOUT-HCM results showing Camzyos efficacy and safety in adolescents with oHCM, achieving significant LVOT reduction with no new safety concerns.

Clinical Trials | 30/03/2026 | By News Bureau |  103

Hope Medicine Reports Positive Phase II Results for First-in-Class Endometriosis Drug

HMI-115 shows significant pain reduction without hormonal disruption, paving the way for global phase III trials.

Clinical Trials | 26/03/2026 | By News Bureau |  201

IMUNON Reports Phase 2 Data Showing Improved Survival in Advanced Ovarian Cancer

IMUNON reports updated Phase 2 data showing improved Overall Survival (OS) with IMNN-001 in advanced ovarian cancer.

Clinical Trials | 26/03/2026 | By News Bureau

Ministry of Ayush and DBT Launch Clinical Study on Ayurveda for TB Treatment

Ministry of Ayush and DBT launch a clinical study on Ayurveda as adjunct therapy for tuberculosis (TB), advancing evidence-based, integrative approaches to strengthen India’s TB elimination efforts.

Clinical Trials | 25/03/2026 | By News Bureau

Arch Biopartners Advances Phase II Trial of LSALT Peptide as New Site Begins Patient Dosing

Arch Biopartners advances LSALT peptide trial for acute kidney injury as new clinical site initiates patient dosing and global expansion plans progress.

Clinical Trials | 24/03/2026 | By News Bureau

Caris Study Shows AI Tool Improves Accuracy in Lung Cancer Diagnosis

Caris Life Sciences finds its GPSai algorithm can identify misdiagnosed lung cancer cases, potentially improving treatment decisions and outcomes through AI-driven molecular profiling.

Clinical Trials | 24/03/2026 | By News Bureau

Pfizer-Valneva Lyme Vaccine Shows Strong Phase-III Efficacy

Pfizer and Valneva’s Lyme disease vaccine candidate showed over 70 percent efficacy in phase-III trials in individuals aged five years and above, with a strong safety profile, as Pfizer prepares for regulatory submissions, marking a key step towards potential approval.

Clinical Trials | 24/03/2026 | By News Bureau

Innovent Doses First Patient in Phase III Trial of Tigulixostat for Gout

Innovent initiates Phase III study of tigulixostat against febuxostat in Chinese gout patients, aiming to deliver improved uric acid control and better safety outcomes.

Clinical Trials | 23/03/2026 | By News Bureau

Harbour BioMed Publishes Positive Phase I Data for HBM9378 in Immunology

Harbour BioMed reports favourable safety and pharmacokinetic profile for HBM9378 in Phase I trial, supporting further development for severe immunological disorders.

Clinical Trials | 23/03/2026 | By News Bureau